All In Biotech

Drug Trial Radar · NCT03575793

A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer

A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer: Big Ten Cancer Research Consortium. BTCRC-LUN17-127

Last checked: Nov 19, 2026Latest source record: Jan 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

39

Actual

Start

Sep 6, 2018

Primary completion

Sep 25, 2023

Study completion Jul 1, 2024

Sponsor

Lead sponsor
Salma SabbourAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
BeyondSpring Pharmaceuticals Inc.; Bristol-Myers Squibb; Rutgers Cancer Institute of New Jersey
First posted
Jul 3, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label Phase I/II study, with a dose escalation part (Phase I) and a single-arm part (Phase II), in patients with recurrent SCLC who progressed after first-line platinum-based chemotherapy and who are candidates for second line therapy. No PK evaluation is planned in this study as nivolumab and ipilimumab are unlikely to alter plinabulin's PK, since the route of excretion is different.

Conditions

  • Lung Cancer
  • SCLC

Interventions

  • NivolumabDrug

    A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1,) with immune checkpoint inhibitory and antineoplastic activities.

  • PlinabulinDrug

    Plinabulin (BPI-2358) is a synthetic, low molecular weight, new chemical entity originally developed by Nereus Pharmaceuticals, Inc., and now by BeyondSpring Pharmaceuticals, Inc. It belongs to the diketopiperazine class of compounds with a chemical name 2, 5-piperazinedione, 3-\[\[5-(1,1-dimethylethyl)-1H-imidazol-4-yl\[methylene\]-6-(phenylmethylene)-, (3Z,6Z) (trivial name t-butyl-dehydrophenylahistin).

  • IpilimumabDrug

    Ipilimumab is a monoclonal antibody that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase I: Maximum Tolerated Dose (MTD)Time frame: Up to 42 days of first Plinabulin dose
  2. Progression-Free Survival (PFS)Time frame: Up to maximum of 9 months

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope

    Duarte, California

  • Moffitt Cancer Center

    Tampa, Florida

  • University of Illinois Cancer Center

    Chicago, Illinois

  • Indiana University Melvin and Bren Simon Cancer Center

    Indianapolis, Indiana

  • Henry Ford Health System

    Detroit, Michigan

  • University of Minnesota

    Minneapolis, Minnesota

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey

  • Erlanger Health System

    Chattanooga, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.